Your shopping cart is currently empty

Lipid U 105, an ionizable cationic lipid (pKa = 6.65), is employed in formulating lipid nanoparticles (LNPs) for delivering circular RNA both in vitro and in vivo. These LNPs, containing lipid U 105 and circular RNA for VEGF-A, enhance VEGF-A levels, boosting the proliferation and migration of human umbilical vein endothelial cells (HUVECs). Moreover, applying these LNPs topically accelerates wound healing in diabetic mice on a high-fat and -sugar diet.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Lipid U 105, an ionizable cationic lipid (pKa = 6.65), is employed in formulating lipid nanoparticles (LNPs) for delivering circular RNA both in vitro and in vivo. These LNPs, containing lipid U 105 and circular RNA for VEGF-A, enhance VEGF-A levels, boosting the proliferation and migration of human umbilical vein endothelial cells (HUVECs). Moreover, applying these LNPs topically accelerates wound healing in diabetic mice on a high-fat and -sugar diet. |
| Molecular Weight | 867.42 |
| Formula | C53H106N2O6 |
| Cas No. | 3049129-14-5 |
| Smiles | O=C(OC(CCCCCCCC)CCCCCCCC)CCCCCN(CCCN(CCO)CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.